Could brain tumor patients stop seizure meds sooner?

NCT ID NCT06442748

Recruiting now Disease control Sponsor: Tata Memorial Centre Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether brain tumor patients who have been seizure-free for 6 months on levetiracetam can safely stop the drug earlier than the standard 2-3 years. 604 adults with primary brain tumors and controlled seizures will be randomly assigned to stop levetiracetam after 6 months or continue for 2-3 years. The goal is to see if a shorter course prevents seizures just as well while reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: levetiracetam
What this could lead to: If successful, this could show that a shorter course of levetiracetam is just as effective as a longer one, reducing side effects and medication burden for brain tumor patients.
What could go wrong: This is a large phase 3 trial, but it is still possible that stopping levetiracetam early leads to more seizures. The results may not apply to all brain tumor types or patients on other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIEPILEPTICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm epilepsy primary brain neoplasm visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIEPILEPTICS BRAIN TUMORS LEVETIRACETAM SEIZURES

Contacts and locations

Locations

Manipal Academy of Higher Education
NOT_YET_RECRUITING

Udupi, Karnataka, 576104, India
Tata Memorial Centre
RECRUITING

Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.